GALT Profile
Galectin Therapeutics Inc. is a dynamic clinical-stage biopharmaceutical company at the forefront of research and development in therapeutic interventions for fibrotic diseases, cancer, and other challenging medical conditions. The company's primary focus lies in the advancement of innovative therapies aimed at addressing liver fibrosis associated with fatty liver disease, non-alcoholic steatohepatitis cirrhosis, and various forms of cancer. Leading its portfolio is belapectin (GR-MD-02), a potent galectin-3 inhibitor currently in Phase III clinical trials. This galactoarabino-rhamnogalacturonan polysaccharide polymer holds promise for significantly impacting patient outcomes in these critical areas of medical need.
In addittion to belapectin, Galectin Therapeutics is actively engaged in the development of GM-CT-01, a promising candidate targeting cardiac and vascular fibrosis, currently in the pre-clinical development stage. The company's robust pipeline also includes exploring the potential of belapectin for treating psoriasis, lung fibrosis, and kidney fibrosis, demonstrating its commitment to addressing a diverse range of medical challenges. Furthermore, Galectin Therapeutics collaborates with Galectin Sciences, LLC, a joint venture co-owned with SBH Sciences, Inc. This collaboration focuses on researching and developing small organic molecule inhibitors of galectin-3 for oral administration, showcasing the company's dedication to exploring innovative therapeutic approaches.
Formerly known as Pro-Pharmaceuticals, Inc., Galectin Therapeutics rebranded in May 2011 to reflect its evolving focus and commitment to therapeutic innovation. Founded in 2000 and headquartered in Norcross, Georgia, the company continues to leverage its expertise, collaborative partnerships, and cutting-edge research to advance novel treatments that have the potential to transform patient care and address significant unmet medical needs.
|
